As of Sep 27
| +0.53 / +4.42%|
The 7 analysts offering 12-month price forecasts for Halozyme Therapeutics Inc have a median target of 16.00, with a high estimate of 20.00 and a low estimate of 6.75. The median estimate represents a +27.90% increase from the last price of 12.51.
The current consensus among 8 polled investment analysts is to Buy stock in Halozyme Therapeutics Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.